Compound Detail

CHEMBL1742466

LANDIOLOL

💊 Approved Drug

Enter ChEMBL ID:

Free Research Context This compound will appear in recent viewed items on the research home for this browser.

Research home View demo workspace

💊 Approved Drug

CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1

ChEMBL ↗ Properties Compare Identifier

Basic Information

ChEMBL ID	CHEMBL1742466
Name	LANDIOLOL
Phase	Approved
Structure Type	MOL
InChI Key	WMDSZGFJQKSLLH-RBBKRZOGSA-N
Therapeutic	✓ Yes

Known Names

AOP-200704 AOP200704 Landiolol LDLL-600 LDLL600 ONO-1101

Targets

Activities

Assay Types

PK Parameters

Publications

Known Names

Indications

Mechanisms

Molecular Properties

509.6

MW (Da)

0.69

ALogP

HBA

HBD

127.8

PSA (Å²)

0.26

QED

Ro5 Violations

Rot. Bonds

Drug Information

Molecule Type	Small molecule
First Approval	2024
Availability	Prescription
Chirality	Single Enantiomer

Routes of Administration

Parenteral

Flags

Natural Product

USAN Stem	-olol
USAN Year	2022

Extended Properties

Molecular Formula	C25H39N3O8
MW	509.60
Aromatic Rings	1
Heavy Atoms	36
NP-Likeness	-0.54

Mechanism of Action

Mechanism	Action Type	Target	Direct	Efficacy
Beta-1 adrenergic receptor antagonist	ANTAGONIST	Beta-1 adrenergic receptor	✓	✓

Indications

Atrial Fibrillation Cardiovascular Diseases Shock, Septic Arrhythmias, Cardiac Atrial Flutter Heart Arrest Tachycardia, Supraventricular

ATC Classification

C07AB14

landiolol

Level 1: CARDIOVASCULAR SYSTEM

Level 2: BETA BLOCKING AGENTS

Literature References

PubMed	DOI	Target Context	# Activities
-	10.6019/CHEMBL4808148	Histone deacetylase 6	2
-	10.1101/2020.04.21.054387	SARS-CoV-2	1

Data from ChEMBL 36 via Core Engine